4 December 2017 Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017
13 November 2017 ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience
7 November 2017 ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017
31 October 2017 ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001
9 October 2017 ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS
11 September 2017 Oryzon Genomics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference and at the 17th Annual Biotech in Europe Forum
28 July 2017 ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017
24 July 2017 ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimer’s Association International Conference (AAIC-2017)